Introgen Therapeutics Inc. said that preliminary data of a Phase III trial showed that Advexin, an investigational therapy that targets the abnormal p53 tumor suppressor function, which is associated with cancer initiation, progression and treatment resistance, significantly increased the survival of patients with head and neck cancer. (BioWorld Today)
Nektar Therapeutics Inc. said it will cease all spending and partnership talks for Exubera after a new analysis of clinical trial data revealed an increased risk of lung cancer. (BioWorld Today)
After receiving a not approvable letter last fall, Endo Pharmaceuticals Inc. said it has decided to withdraw its supplemental new drug application for its migraine headache drug Frova as a short-term preventive treatment for menstrual migraines. (BioWorld Today)
Amgen Inc.'s experimental osteoporosis drug, denosumab, met all bone mineral density (BMD) endpoints for all skeletal sites in a two-year, 332-patient Phase III study. (BioWorld Today)
